NasalCrom Availability: What Providers and Prescribers Need to Know in 2026

Patients are increasingly presenting with confusion about NasalCrom (cromolyn sodium nasal spray) availability in the context of the broader cromolyn shortage news. As a prescriber, understanding the nuances of cromolyn product availability will help you counsel patients accurately, write prescriptions effectively, and recommend appropriate alternatives when needed.

Current Availability Status: NasalCrom vs. Gastrocrom

The key clinical distinction providers must understand:

• NasalCrom (cromolyn sodium nasal spray, 5.2 mg/spray): OTC product. Not in FDA shortage as of 2026. Generally available at major pharmacy chains. Indicated for seasonal and perennial allergic rhinitis.
• Gastrocrom (cromolyn sodium oral solution, 100 mg/5 mL): Prescription product. Active FDA shortage since mid-2023, ongoing through 2026. Indicated for mastocytosis and mast cell activation syndrome (MCAS).

These are not interchangeable. Patients seeking Gastrocrom cannot substitute NasalCrom for systemic mast cell symptom management. Advise your team accordingly to avoid this counseling error.

Why Patients Report Difficulty Finding NasalCrom

Despite not being in active shortage, NasalCrom presents access challenges for some patients:

• Low inventory priority: NasalCrom is a niche OTC product with modest sales volume. Many independent and rural pharmacies do not stock it.
• Seasonal demand spikes: During peak pollen seasons, stock can deplete faster than reorder cycles.
• Insurance coverage limitations: As an OTC product, NasalCrom is generally not covered by insurance without a prescription. Patients without written prescriptions pay full retail ($15–$28 OTC). When prescribed, it becomes eligible for insurance coverage and discount programs.
• Cromolyn shortage confusion: Patients who search for "cromolyn shortage" find Gastrocrom shortage information and incorrectly conclude their nasal spray is also unavailable.

Clinical Profile of NasalCrom for Allergic Rhinitis

NasalCrom (cromolyn sodium) is a mast cell stabilizer that inhibits IgE-mediated release of histamine, cysteinyl leukotrienes, and other mediators from sensitized mast cells. Key clinical characteristics:

• Onset: Takes several days to begin working; optimal effect in 1–2 weeks. Best started 1–2 weeks before expected allergen exposure.
• Dosing: 1 spray per nostril every 4–6 hours (max 6 times daily); ages 2+.
• Drug interactions: No known significant interactions. Can be safely combined with oral antihistamines, intranasal steroids, and decongestants.
• Safety: Minimal systemic absorption (<7% intranasal dose). No growth suppression in children. Safe in pregnancy if needed (Category B equivalent considerations). Good tolerability profile.
• Limitations: Multiple daily dosing (3–4x/day) is a practical barrier. Efficacy generally lower than intranasal corticosteroids for moderate-to-severe rhinitis.

When NasalCrom Is Preferred Over Intranasal Steroids

Although intranasal corticosteroids are first-line per most guidelines, NasalCrom may be preferred in specific clinical scenarios:

• Patients with concerns about steroid exposure (even though intranasal steroids have minimal systemic absorption)
• Pediatric patients where the non-steroidal profile is valued by parents
• Patients with mild seasonal symptoms where a predictable prevention strategy is desired
• Add-on therapy for patients who are already on a nasal steroid but still experiencing symptoms

How to Help Patients Access NasalCrom: Provider Tips

Practical steps to improve patient access:

1. Write a prescription. Even though NasalCrom is OTC, a prescription allows insurance billing and unlocks GoodRx and SingleCare discount pricing. Generic cromolyn sodium nasal spray may be as low as $6–$7 with coupon codes.
2. Direct patients to large chains or online. CVS, Walgreens, Walmart, and online retailers (Amazon, pharmacy websites) are the most reliable sources.
3. Recommend medfinder for Providers. medfinder for Providers calls pharmacies on your patients' behalf to identify which ones have their medication in stock — reducing call-back burden and prescription abandonment.

Alternatives When NasalCrom Is Unavailable or Inadequate

If a patient cannot locate NasalCrom or reports inadequate symptom control, consider:

• Intranasal corticosteroids (first-line): Fluticasone (Flonase), triamcinolone (Nasacort), budesonide (Rhinocort). All available OTC; daily dosing improves adherence.
• Intranasal antihistamines: Azelastine (Astepro, OTC) or olopatadine (Patanase, Rx). Fast onset; useful for acute symptom management.
• Combination therapy: Dymista (azelastine + fluticasone, Rx) for moderate-to-severe rhinitis not controlled by monotherapy.
• Oral antihistamines: Cetirizine, loratadine, or fexofenadine as adjunct or monotherapy for mild symptoms.

For a more detailed provider guide, see How to Help Your Patients Find NasalCrom in Stock.